Generic Name: enasidenib
Drug Class: Targeted Therapy Medications
Approval Status: Approved
Generic Version Available: No
Idhifa is an IDH2 inhibitor approved for adults with acute myeloid leukemia with IDH2 mutations that does not respond to prior treatment.
Idhifa inhibits isocitrate dehydrogenase-2, an enzyme that plays a role in cellular metabolism. The drug targets mutant versions of the enzyme produced by cancerous blood cells. A study showed that 23 percent of people who used Idhifa achieved complete remission and normalization of blood cell counts. It was approved in 2017.
Idhifa is a tablet taken once daily until disease progression or unacceptable side effects occur.
Idhifa is usually well tolerated. The most common side effects include nausea, vomiting, diarrhea, loss of appetite and elevated. The Idhifa label has a warning about differentiation syndrome, a set of symptoms including swelling and shortness of breath that can occur when myeloid cells mature. Idhifa may cause fetal harm if used during pregnancy.
For More Info: https://www.idhifa.com
Patient Assistance Program Info: https://www.idhifa.com/resources-and-financial-support/
Last Reviewed: November 29, 2018